Marshall Financial Group LLC Has $1.15 Million Holdings in Agilent Technologies, Inc. (NYSE:A)

Marshall Financial Group LLC grew its holdings in Agilent Technologies, Inc. (NYSE:A) by 4.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,571 shares of the medical research company’s stock after buying an additional 328 shares during the period. Marshall Financial Group LLC’s holdings in Agilent Technologies were worth $1,151,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Van ECK Associates Corp lifted its position in Agilent Technologies by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock worth $442,011,000 after acquiring an additional 183,716 shares during the last quarter. Vestal Point Capital LP acquired a new stake in Agilent Technologies during the 3rd quarter worth approximately $14,848,000. Empowered Funds LLC boosted its stake in Agilent Technologies by 29.8% in the 3rd quarter. Empowered Funds LLC now owns 30,978 shares of the medical research company’s stock valued at $4,592,000 after purchasing an additional 7,111 shares during the period. Czech National Bank grew its holdings in Agilent Technologies by 6.5% in the 3rd quarter. Czech National Bank now owns 59,456 shares of the medical research company’s stock valued at $8,828,000 after buying an additional 3,612 shares in the last quarter. Finally, S.E.E.D. Planning Group LLC increased its position in Agilent Technologies by 12.7% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock worth $5,721,000 after buying an additional 4,805 shares during the period.

Wall Street Analyst Weigh In

A has been the subject of several recent research reports. Wells Fargo & Company cut their price target on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Bank of America dropped their price target on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Citigroup increased their price objective on shares of Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. Finally, Evercore ISI boosted their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $143.62.

Agilent Technologies Stock Performance

Shares of A opened at $151.24 on Friday. The firm’s fifty day simple moving average is $138.43 and its two-hundred day simple moving average is $138.06. Agilent Technologies, Inc. has a 12 month low of $124.16 and a 12 month high of $155.35. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $43.19 billion, a P/E ratio of 34.22, a price-to-earnings-growth ratio of 4.12 and a beta of 1.06.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. The firm had revenue of $1.70 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The company’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.38 EPS. As a group, analysts predict that Agilent Technologies, Inc. will post 5.56 EPS for the current year.

Agilent Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st were paid a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date of this dividend was Tuesday, December 31st. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s payout ratio is 22.40%.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.